Summary & Overview
HCPCS J3263: Injection, toripalimab-tpzi, 1 mg
HCPCS Level II code J3263 denotes the injectable immunotherapy agent toripalimab-tpzi, billed per milligram (1 mg unit). As a biologic oncology therapy, this drug-level HCPCS code is used across outpatient infusion settings and physician offices for administration of toripalimab-based treatment. Nationally, accurate coding of high-cost biologics like toripalimab-tpzi matters for provider reimbursement, payer utilization management, and drug inventory control.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and service context, typical sites of service, common modifiers (listed separately), and what to expect in payer coverage policies. The publication also summarizes benchmark concepts and policy considerations relevant to billing high-cost injectable oncology agents, and highlights where data is unavailable.
This summary is intended to inform coding staff, revenue cycle professionals, and policy analysts about the HCPCS Level II code J3263, the clinical context of toripalimab-tpzi administration, and the payer landscape for national-level discussion of coverage and billing practices.
Billing Code Overview
HCPCS Level II code J3263 represents Injection, toripalimab-tpzi, 1 mg. This code is used to bill for the drug product toripalimab-tpzi administered as an injectable formulation.
Service Type: Drug administration (intravenous or subcutaneous injectable therapy)
Typical Site of Service: Hospital outpatient department, physician office, or infusion center, where oncology and specialty immunotherapy infusions are commonly provided.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with recurrent metastatic nasopharyngeal carcinoma is scheduled to receive intravenous immunotherapy with toripalimab (PD-1 inhibitor) as part of systemic cancer therapy. The medication is administered in an outpatient infusion center or oncology clinic by an oncology nurse under the supervision of a medical oncologist. Prior to infusion, the patient undergoes verification of identity, review of allergies, review of recent laboratory studies (complete blood count, hepatic and renal panel), confirmation of indication and dose calculation based on the physician order, and verification of payer authorization. The pharmacist compounds or dispenses the billed product J3263 in a single-dose vial or syringe; the injection is administered intravenously per protocol, with vital signs monitored before, during, and after infusion and an observation period for infusion-related reactions. Documentation includes indication, dose in mg, lot number, route, site, time, patient tolerance, and any administration-related events. For waste billing, unused drug is documented and modifiers such as JW (drug discarded/not administered to patient) or JZ (no drug provided) are applied when appropriate. Typical sites of service are outpatient hospital infusion centers, freestanding oncology infusion clinics, and physician offices with infusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|